Efzimfotase alfa

• Description :

  Efzimfotase alfa (ALXN-1850) is enzyme replacement therapy agent targeting the deficiency of tissue-nonspecific alkaline phosphatase (TNSALP) . Efzimfotase alfa functions by hydrolyzing the substrates of TNSALP, reducing the concentrations of substrates such as inorganic pyrophosphate (PPi) and pyridoxal 5′-phosphate (PLP) . Efzimfotase alfa is promising for research of hypophosphatasia (HPP) [1][2].

• Product Name Alternative :

  ALXN-1850

• UNSPSC :

  12352203

• Target :

  Phosphatase

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Smiles :

  [Efzimfotasealfa]

• References & Citations :

  [1]Dahir KM, et al. Medical Management of Hypophosphatasia: Review of Data on Asfotase Alfa. Curr Osteoporos Rep. 2025 Mar 18;23 (1) :14.|[2]Dahir KM, et al. Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia. J Bone Miner Res. 2024 Sep 26;39 (10) :1412-1423.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 3

• CAS Number :

  [2746354-58-3]